On June 7 at noon (ET), ASCO will host a one-hour webinar for participants to learn more about the Quality Oncology Practice Initiative (QOPI®) Certification Program.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO strongly opposes the Administration’s proposed cuts to federal agencies that support biomedical research and Medicaid for Fiscal Year 2018, including a 21 percent proposed funding cut for the National Institutes of Health (NIH), a 20 percent proposed funding cut for the National Cancer Institute (NCI), and reducing Medicaid funding by more than $600 billion. Such extreme reductions to programs that are critical to research will fundamentally damage our nation’s progress in treating patients and will irreversibly harm our nation’s already fragile biomedical research infrastructure.
CancerLinQ LLC and the Society of Gynecologic Oncology (SGO) have announced a partnership where the SGO will provide expert guidance and insight on the management of gynecologic cancers for the CancerLinQ® platform. CancerLinQ LLC is a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO) that is developing and operating CancerLinQ®, a real-world, big data initiative focused on cancer patient medical information, aimed at improving the quality of patient care and outcomes.
CancerLinQ, LLC CEO, Kevin Fitzpatrick will join leaders of the cancer community including the Cancer Support Community and the American Cancer Society in speaking at the 2017 eyeforpharma Oncology Market Access & Pricing, taking place in Philadelphia.
On May 23, 2017, the U.S. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA® , Merck & Co.) for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options or with MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
On May 19, ASCO submitted comments to Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, on the FDA’s proposed guidance for industry on demonstrating interchangeability of biosimilars with a reference product. In ASCO’s comments to the FDA, the society took the opportunity to reiterate its strongly held position that physicians and patients should have the ability to select evidence-based treatment options – including the specific biologic product – most appropriate for the patients’ circumstance.
On May 24 at noon (ET), ASCO will host a one-hour webinar for participants to learn more about the Quality Oncology Practice Initiative (QOPI®) Certification Program.
The American Academy of PAs (AAPA) and CancerLinQ LLC announced today that they will be entering a partnership, with AAPA contributing expertise to the CancerLinQ® platform and potentially leveraging CancerLinQ Discovery™ for queries that will assist research efforts in the PA community aimed at improving the quality of patient care.
On May 22, CancerLinQ LLC Chief of Strategic Alliances Jennifer L. Wong will be speaking at an event hosted by the MIT Enterprise Forum (MITEF) of New York City titled “Outsmarting Cancer: How New Technologies are Tackling a Cure.”
On May 18, 2017, the U.S. Food and Drug Administration granted regular approval to pembrolizumab (KEYTRUDA® , Merck and Co., Inc.) for patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
In April 2017, the American Society of Pediatric Hematology/Oncology (ASPHO) Board of Trustees voted unanimously to formally endorse the newest version of ASCO and the Oncology Nursing Society’s (ONS) joint chemotherapy administration safety standards.
In a letter of intent (LOI) to the Physician-Focused Payment Model Technical Advisory Committee (PTAC), an advisory group to the Centers for Medicare & Medicaid Services (CMS), ASCO expressed its intent to submit a physician payment reform model for PTAC review and eventual consideration by CMS as an advanced alternative payment model (APM) under the Medicare Access and CHIP Reauthorization Act (MACRA) and the Quality Payment Program (QPP).
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO®, has announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Rubinstein will oversee the team working to securely process and analyze the CancerLinQ® platform's patient data from millions of electronic health records to give personalized insights than can improve the quality of care for patients with cancer.
The National Institutes of Health (NIH) and Food and Drug Administration (FDA) Joint Leadership Council announced the release of the final clinical trial protocol template. Reflecting public input from more than 60 individuals and 200 comments, the template is designed to increase protocol development efficiency, save time and money in medical product development, and help investigators develop more consistent, complete protocols.
On May 6, leadership from CancerLinQ LLC presented at the Oncology Nursing Society (ONS) Congress in Denver where they delivered a joint presentation on their recent collaboration with ONS and the newly established CancerLinQ® Ambassadors Program – a national practice engagement initiative to drive improved quality and outcomes.